Table 4.

Inhibition of bursting by subtype-selective ligands

Ligand	Receptor(s) activated	% inhibition of burst rate	Number of slices
SST	All	58.6 ± 4%	11
Octreotide	SST2 > SST3	33.9 ± 4%*	9
l-796,778	SST3	5.2 ± 3.4* , **	5
J-2156	SST4	21.8 ± 3%*	10
l-803,087	SST4	2.1 ± 5.7%* , **	8
Octreotide + J-2156	SST2 + SST4	47.0 ± 5	6
SST + SRA880 a	All but SST1	47.0 ± 2	7
SST + ACQ090 b	All but SST3	46 ± 5	6

Concentration is 1 μm for all drugs except when octreotide and J-2156 are coapplied (0.5 μm each).

^aSST₁-selective antagonist.

^bSST₃-selective antagonist.

*Significantly different from SST alone (p < 0.05; unpaired t test);

**no significant inhibition of burst rate (p > 0.05; paired t test).